We are delighted to announce that our Vice President of Clinical Development, Erin Tireman, Psy.D, will now be overseeing medical writing services as an expansion of her current leadership role within Lotus’ Scientific Services division.
Fast-growing CRO utilizes Veeva Vault Clinical Suite to substantially decrease startup time — Veeva Systems (NYSE: VEEV) today announced that Lotus Clinical Research expanded its partnership with Veeva..
Lotus Clinical Research worked closely with Pacira on this successful pivotal Phase 3 trial in bunionectomy, providing scientific consulting and conducting the study within our CRO and the ERG site network.
News & Press Lotus Clinical Research worked closely with Pacira on this successful pivotal Phase 3 trial in total knee arthroplasty (TKA), providing scientific consulting
Below please find my comments on FDA’s draft document: Development of Non-Opioid Analgesics for Acute Pain: Guidance for Industry, dated February 7, 2022. I am a board-certified anesthesiologist and Chief Scientific Officer of Lotus Clinical Research, LLC, a contract research organization, regulatory consulting firm and research site network specializing in analgesic clinical trials.
Lotus Clinical Research worked closely with Innocoll on this successful pivotal Phase 3 trial in abdominoplasty, providing scientific and regulatory consulting and conducting the study within our CRO and the ERG site network.
Lotus Clinical Research worked closely with Innocoll on the design of both new Phase 3 trials, and is currently conducting both studies within our CRO and site network:
Innocoll Biotherapeutics plc Announces First Patients In Phase 3 Clinical Trials for Label Expansion of Xaracoll® (bupivacaine hydrochloride) Implant
Lotus Clinical Research has worked with Concentric for several years and through multiple studies on their novel non-opioid analgesic vocacapsaicin. Recently, Lotus CRO has been instrumental in the study design..
All data used in this analysis is from public sources, and is linked/ cited where possible. INTRODUCTION/ HISTORY Heron Therapeutics’ Zynrelef (formerly called HTX-011) represents
Baudax Bio Non-Opioid Pain Drug Approval: In February, FDA granted approval to longtime Lotus client/ collaborator Baudax Bio’s non-opioid postsurgical pain therapy ANJESO. Lotus designed and performed both the Phase 2 and Phase 3 programs for this drug, with extensive scientific..
In September 2019, Lotus acquired HD Research, a network of specialty US analgesic research sites run by board certified anesthesiologists Harold Minkowitz, MD and David
At Lotus Clinical Research, the safety of our patients, employees and customers remains our highest priority.
In the coming weeks and months, in accordance with public health department…
© 2023 Lotus Clinical Research, LLC. All Rights Reserved
